BioTuesdays

Category - News

Rock Creek Pharmaceuticals Logo
Markets

Maxim starts Rock Creek Pharma at buy

Maxim Group has initiated coverage of Rock Creek Pharmaceuticals (NASDAQ:RCPI) with a “buy” rating and 12-month price target of $4. The stock closed at 83 cents on Monday. Rock Creek’s lead product, anatabine citrate...

October 20, 2015
Profound Medical Logo
Developments

Profound Medical presents TULSA-PRO data

Twelve-month data from Profound Medical’s (TSXV:PRN) Phase 1 clinical trial of its TULSA-PRO medical device were presented at the European Symposium on Focused Ultrasound Therapy in London. TULSA is a minimally invasive...

October 16, 2015
Viking Therapeutics Logo
Markets

Feltl starts Viking Therapeutics at strong buy

Feltl & Co. has launched coverage of Viking Therapeutics (NASDAQ:VKTX) with a “strong buy” rating and price target of $17.50. The stock closed at $6.90 on Wednesday. “We anticipate the company executing on multiple...

October 15, 2015
Prima BioMed
Markets

HCW starts Prima BioMed at buy

H.C. Wainwright has initiated coverage of Prima BioMed (NASDAQ:PBMD) with a “buy” rating and $3 price target. The stock closed at $1.22 on Tuesday. Australia-based Prima is developing novel checkpoint modulators (CPMs)...

October 14, 2015
Titan Pharmaceuticals Logo
Markets

Titan Pharma to uplist to NASDAQ

Titan Pharmaceuticals (OTCQB:TTNPD) has received approval to list its common stock on the NASDAQ Capital Market, effective at the opening on Monday, Oct.12, under the symbol TTNP. “Uplisting to the NASDAQ Capital Market...

October 8, 2015
Immune Pharmaceuticals
Markets

Roth starts Immune Pharma at buy

Roth Capital Partners has initiated coverage of Immune Pharmaceuticals (NASDAQ:IMNP) with a “buy” rating and $6 price target. The stock closed at $1.21 on Wednesday. Immune is developing bertilimumab in combating...

October 8, 2015